Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Eli Lilly and Company
65 Articles Available
0
3
Can't find what you're looking for? Try our
advanced search
.
M&A
Lilly Announces Acquisition of Protomer Technologies
PR-M07-21-06
Breakthrough Results
Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with Preserved Ejection Fraction
PR-M07-21-04
Phase III
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
PR-M04-21-028
COVID-19
Lilly Modified COVID-19 Purchase Agreement for Bamlanivimab and Etesevimab Together
PR-M04-21-010
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
PR-M11-20-022
COVID-19
Lilly Announces Agreement with U.S. Government to Supply 300,000 Vials of Investigational Neutralizing Antibody to Fight COVID-19
PR-M10-20-18
Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial
PR-M10-20-09
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
PR-M06-20-NI-020
COVID-19 Clinical Testing
Lilly Begins Clinical Testing of Therapies for COVID-19
PR-M04-20-NI-018
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
PR-M04-20-NI-010
Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic
PR-M04-20-NI-004
Coronavirus
Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
PR-M03-20-NI-020
Partnership
Eli Lilly and Company to Partner in Support of the Olympic and Paralympic Games Tokyo 2020
PR-M02-20-NI-030
Investment
Governor Cooper Announces Over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
PR-M01-20-NI-034
M&A
Lilly Announces Agreement to Acquire Dermira
PR-M01-20-NI-032
Drug Pricing
Lilly Expands Insulin Affordability Options
PR-M01-20-NI-028
Investment
Lilly Announces $400 Million Capital Investment in Manufacturing Facilities in Indianapolis
PR-M11-19-NI-028
Phase III
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
PR-M09-19-NI-001
Licensing Agreement
Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China
PR-M08-19-NI-076
Research
Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Dementia
PR-M08-19-NI-033
Migraine Prevention
Eli Lilly Looking to Boost Sales of Migraine Med with New Data on Emergency Room Visits
PAO-M08-19-NI-004
FDA Approval
FDA Approves First Treatment for Severe Hypoglycemia that can be Administered Without an Injection
PR-M07-19-NI-072
Leadership
Lilly Announces Changes in Senior Leadership
PR-M07-19-NI-037
FDA Fast Track
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
PR-M06-19-NI-058
«
0
3
»
.svg)